White Papers Gated White Paper
White Paper
Signal-to-Action: An AI-Enabled RBM Model
From risk indicators to actionable site-level interventions.
24 pagesFebruary 2026White Paper
About this white paper
What's inside
From risk indicators to actionable site-level interventions. This research-grade white paper distills field experience from production deployments into a structured framework your clinical, biometrics, QA, and IT leaders can act on this quarter.
Key takeaways
What you'll learn
- A reference framework for governing agentic AI in GxP-regulated workflows.
- Reviewer-in-the-loop patterns that hold up to internal audit and inspection.
- Validation, audit-trail, and escalation controls across the agent lifecycle.
- Quantified impact on cycle time, cost, and quality across recent deployments.
- A 90-day implementation path from pilot to production rollout.
About the author
Marcus Lehmann
Principal, Biometrics Strategy
Marcus has 18 years in clinical biometrics across Top-20 pharma and global CROs. He writes about agentic delivery models for SDTM, ADaM, and TLF.
Looking for AI Workforce for clinical trials?
Explore our AI Workforce Platform
See how AI agents are transforming study startup, data management, oversight, and regulatory submissions.